The Benefit of Bermekimab in Patients With Systemic Sclerosis
Clinical Efficacy of Inhibition of Organ Dysfunction Through Bermekimab in Systemic Sclerosis: A Proof- Of-Concept Double-Blind Randomized Clinical Trial (the Light Trial) Clinical Efficacy of Inhibition of Organ Dysfunction Through Bermekimab in Systemic Sclerosis: A Pro ...
Scleroderma, Systemic
Drug: MABp1(Bermekimab) OR Placebo;Drug: MABp1(Bermekimab)